PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation

Journal of Surgical Research

Volumn 185, Issue 1, 2013, Pages 225-230

  Gedaly, Roberto ^a   Galuppo, Roberto ^a   Musgrave, Yolanda ^a   Angulo, Paul ^a   Hundley, Jonathan ^a   Shah, Malay ^a   Daily, Michael F ^a   Chen, Changguo ^a   Cohen, Donald A ^a   Spear, Brett T ^a   Evers, B Mark ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Hepatocellular carcinoma; Liver cancer stem cells; PKI 587; Sorafenib

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BETA ACTIN; CD133 ANTIGEN; CD24 ANTIGEN; HERMES ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PKI 587; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; S6 KINASE; SORAFENIB; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

HEPATOCELLULAR CARCINOMA; LIVER CANCER STEM CELLS; PKI-587; SORAFENIB;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; NEOPLASTIC STEM CELLS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); RAF KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRIAZINES;

EID: 84886716678     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.05.016     Document Type: Article

References (21)

1. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907
2. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312
3. A. Lachenmayer, Y. Hoshida, and J.M. Llovet Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma Gastroenterology 139 2010 692
4. D. Strumberg Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment Drugs Today 41 2005 773
5. T. Lapidot, C. Sirard, and J. Vormoor A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645
6. J.E. Visvader, and G.J. Lindeman Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nat Rev Cancer 8 2008 755
7. T. Chiba, K. Kita, and Y.-W. Zheng Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties Hepatology 44 2006 240
8. A. Suetsugu, M. Nagaki, H. Aoki, T. Motohashi, T. Kunisada, and H. Moriwaki Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells Biochem Biophys Res Commun 351 2006 820
9. C.M. Tong, S. Ma, and X.-Y. Guan Biology of hepatic cancer stem cells J Gastroenterol Hepatol 26 2011 1229
10. R. Gedaly, P. Angulo, J. Hundley, M.F. Daily, C. Chen, and B.M. Evers PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation J Surg Res 176 2012 542
11. R. Gedaly, P. Angulo, and J. Hundley PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways Anticancer Res 30 2010 495
12. N.A. Lobo, Y. Shimono, D. Qian, and M.F. Clarke The Biology of cancer stem cells Annu Rev Cell Dev Biol 23 2007 675
13. Z. Yu, T.G. Pestell, M.P. Lisanti, and R.G. Pestell Cancer stem cells Int J Biochem Cell Biol 44 2012 2144
14. A.H. Yin, S. Miraglia, and E.D. Zanjani AC133, a novel marker for human hematopoietic stem and progenitor cells Blood 90 1997 5002
15. S. Yin, J. Li, and C. Hu CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity Int J Cancer 120 2007 1444
16. L.S. Piao, W. Hur, and T.-K. Kim CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma Cancer Lett 315 2012 129
17. J. Ji, and X.W. Wang Clinical implications of cancer stem cell biology in hepatocellular carcinoma Semin Oncol 39 2012 461
18. Z. Zhu, X. Hao, and M. Yan Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma Int J Cancer 126 2010 2067
19. T.K.W. Lee, A. Castilho, V.C.H. Cheung, K.H. Tang, S. Ma, and I.O.L. Ng CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation Cell Stem Cell 9 2011 50
20. A. Bellizzi, S. Sebastian, and P. Ceglia Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis J Cell Physiol 228 2013 408
21. S. Ma Biology and clinical implications of CD133(+) liver cancer stem cells Exp Cell Res 319 2013 126